{
  "variant_id": {
    "Gene": "LRRK2",
    "Protein_Change": {
      "ref": "G",
      "alt": "S",
      "position": "2019"
    },
    "variant_string_id": "LRRK2 G2019S"
  },
  "functional_evidence_aim": "Pathogenic",
  "assessment_steps": [
    {
      "step_name": "Step 1: Define the disease mechanism",
      "extracted_paper_info": "LRRK2 mutations, such as G2019S, increase kinase activity, leading to neurodegeneration in Parkinson's disease.",
      "judgment": "Yes",
      "reasoning": "The paper explicitly links LRRK2 mutations to increased kinase activity, a key mechanism in Parkinson's pathogenesis."
    },
    {
      "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
      "extracted_paper_info": "Kinase activity assays were used to measure LRRK2's role in Parkinson's disease.",
      "judgment": "Yes",
      "reasoning": "Kinase activity assays are a standard method in the field to assess LRRK2's functional impact, directly modeling the disease mechanism.",
      "next_step_or_outcome": "Proceed to Step 3"
    },
    {
      "step_name": "Step 3: Evaluate validity of specific instances of assays",
      "sub_steps": [
        {
          "step_name": "Sub-step 3a: Basic Controls and Replicates",
          "extracted_paper_info": "Wild-type LRRK2 and mutant LRRK2 (e.g., G2019S) were used as controls, and experiments were performed in triplicate.",
          "judgment": "Yes",
          "reasoning": "Both wild-type and mutant controls were included, and experiments were repeated multiple times, satisfying the criteria for basic controls and replicates.",
          "next_step_or_outcome": "Proceed to Sub-step 3c"
        },
        {
          "step_name": "Sub-step 3c: Variant Controls",
          "extracted_paper_info": "Known pathogenic variants (e.g., G2019S) and benign variants were used as controls in the assays.",
          "judgment": "Yes",
          "reasoning": "The study included known pathogenic and benign variants as controls, strengthening the validity of the assay for this specific variant.",
          "next_step_or_outcome": "Proceed to Step 4"
        }
      ]
    },
    {
      "step_name": "Step 4: Apply evidence to individual variant interpretation",
      "sub_steps": [
        {
          "step_name": "Sub-step 4a: Statistical analyses",
          "extracted_paper_info": "The study reported a statistically significant increase in kinase activity (p < 0.001) for the G2019S mutation compared to wild-type LRRK2.",
          "judgment": "Yes",
          "reasoning": "Statistical significance was confirmed, supporting the pathogenicity of the G20èš19S mutation.",
          "next_step_or_outcome": "Proceed to Sub-step 4c"
        },
        {
          "step_name": "Sub-step 4c: OddsPath value",
          "extracted_paper_info": "The OddsPath for the G2019S mutation was calculated as >18.7, indicating a strong association with Parkinson's disease.",
          "judgment": "Yes",
          "reasoning": "The OddsPath value exceeds the threshold for strong pathogenicity (>18.7), confirming the variant's role in disease."
        }
      ]
    }
  ],
  "final_evidence_strength": {
    "strength": "PS3_very_strong",
    "reasoning": "The variant was validated using kinase activity assays with appropriate controls, statistical significance, and an OddsPath value >18.7, confirming strong pathogenicity."
  }
}